The FDA has narrowly beaten the European Medicines Agency (EMA) to the most appr...
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to so...
The Lonza CEO said the company is not under any pressure to exit the Capsules an...
Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug...
IMPACT Therapeutics has received the China NMPA marketing authorisation for Sena...
AbbVie and Simcere Zaiming have announced an option-to-license agreement for the...
Incyte told JP Morgan attendees of plans for four launches in 2025, beginning wi...
Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get...
While US earnings grew in 2024, revenues in China were hurt by ongoing investiga...
Insmed is set to challenge the Duchenne muscular dystrophy (DMD) treatment space...
Be Biopharma has secured $92m in a Series C financing round to advance its clini...
Eli Lilly has received approval from the US FDA for Omvoh to treat moderately to...
AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflam...
At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client...
CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 20...
